'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
about
The Juxtamembrane Region of the EGF Receptor Functions as an Activation DomainSomatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCDifferent efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysisNovel agents in development for advanced non-small cell lung cancer.Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceHER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reportsAcquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases.EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma.Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
P2860
Q27646344-1155C710-8D23-4534-AF54-36D22DE40884Q33671646-9D6C9892-31D7-4567-8270-2FD0416D8A23Q33779181-FE6CAC4D-B726-4B0E-9684-467F7C3A0848Q34002791-DD887041-657C-43CE-87BC-01C6A37308F0Q34041701-1B675266-EFF0-4617-8482-96E8CF2CD33CQ34130681-7DD5323A-59C5-4B02-A210-D54CAABDEE33Q34311186-0F461C94-CBCB-45E9-9FA4-EC3CC2B1984EQ34333839-C5A6AC96-BEA9-4F41-97B6-8D02EA3D7BDCQ34389263-68907EC2-FCF5-49B4-AEEC-B61474E9FFA4Q36027021-9364A7D9-4592-45C7-882E-48C31E5988FAQ36352476-A149E1BE-31C2-44D5-AB1B-FB3E93A0458DQ36366489-A92315B9-B8F8-4D49-BDBC-2A99B5DEAE38Q36503084-2C168A7D-ACE3-40BF-9DBC-AB148C616D37Q36751137-4612DC4B-004E-4D0D-A79D-FFB16AD9AB69Q36882732-7A89C3B7-6055-4478-A002-074712732AD1Q37334996-37A556EA-55A2-4967-9727-A820C0B318C6Q37344500-7DA80D07-2414-40C7-A6CA-AB2C2795DDCEQ37379113-642F0173-BE73-496D-9DED-1ADDB132FCEFQ37566609-4FE4CBFE-FC3B-4AFC-B449-BB73A22273B8Q39129178-382F1A93-3504-44E3-8383-E2D5524E7994Q39163315-95E6F748-1803-432E-B74A-430DDF9F96CCQ41472672-D9CD1438-2FA6-4839-A5F6-0C708E351F7DQ41852971-D72938D9-BEFD-4DA4-9801-5BCAFD26189FQ42731684-5A5B34D2-853F-4810-B06D-0695BDA61ECCQ47611571-8A626498-927C-4DA2-98BA-5452EC8B094CQ47695177-41AAE7C3-DE29-4BC2-AC44-4DF17686A874Q47864863-C6AB5D17-81FF-484F-85F0-CFA4D6E11EC3Q49379624-D5C7C414-6471-4837-B738-B8613A0ED500Q54411624-8B6716E9-B2AA-4D36-8062-CDE22B6BF484
P2860
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@ast
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@en
type
label
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@ast
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@en
prefLabel
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@ast
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@en
P2093
P2860
P356
P1476
'Classical' but not 'other' mu ...... ith non-small cell lung cancer
@en
P2093
A G Pallis
A Koutsopoulos
A Voutsina
Ar Kalikaki
D Mavroudis
E Briasoulis
E Stathopoulos
J Souglakos
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604068
P407
P577
2007-11-13T00:00:00Z